Compare BSTZ & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSTZ | OGN |
|---|---|---|
| Founded | 2019 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | N/A | 2020 |
| Metric | BSTZ | OGN |
|---|---|---|
| Price | $22.37 | $6.89 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.75 |
| AVG Volume (30 Days) | 178.6K | ★ 4.2M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 8.31% | 1.16% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.71 | ★ 0.72 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | N/A | $0.42 |
| Revenue Next Year | N/A | $1.67 |
| P/E Ratio | $31.33 | ★ $9.60 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.22 | $6.18 |
| 52 Week High | $23.47 | $15.88 |
| Indicator | BSTZ | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.56 | 36.47 |
| Support Level | $22.17 | $6.48 |
| Resistance Level | $23.13 | $7.74 |
| Average True Range (ATR) | 0.44 | 0.37 |
| MACD | -0.07 | -0.08 |
| Stochastic Oscillator | 21.35 | 23.28 |
BlackRock Science and Technology Trust II is a non-diversified, closed-end management investment company. The trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation. Its portfolio consists of Equity Securities, Options, Preferred Securities, Convertible Securities, Depositary Receipts, Non-U.S. Securities, Emerging Markets Investments, Restricted and Illiquid Investments, Private Company Investments, Corporate Bonds, and other investments. The trust seeks to Invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range from the development, advancement, and use of science and/or technology.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.